Research area · week to 3 Oct 2026

Atrial Fibrillation Management and Outcomes

Moving in JAMA.

Moved this week: 1

Rebuilt 3 October 2026 at 4:05 pm AEST

Moved this week

Everything that moved →

Weight Loss in Older Patients With Persistent Atrial Fibrillation: The LOSE-AF Randomized Clinical Trial.
JAMA · 21 July 2026 · Multicenter Study
Read the brief in JClub
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42160044
Open in JClub

Latest in Atrial Fibrillation Management and Outcomes

Newest first · last 60 days

CARDIAC-FM: A Generalizable Multimodal Foundation Model Integrating ECG and Cardiac MRI
medRxiv · 14 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.03.16.26348526
Open in JClub
Image-based deep learning for emergency electrocardiogram classification
medRxiv · 11 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.06.18.26355968
Open in JClub
Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.
New England Journal of Medicine · 31 Aug 2026 · Journal Article
Catheter-directed thrombolysis reduces the risk of death, recurrence, or cardiorespiratory collapse within 7 days in patients with intermediate-high-risk pulmonary embolism, with only minimal bleeding risks.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42678032
Open in JClub
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.
Nature Medicine · 29 Aug 2026 · Journal Article
Potent P2Y12 inhibitors combined with DOACs increase bleeding risk without reducing ischemic events in atrial fibrillation and acute coronary syndrome patients.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42668287
Open in JClub
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
New England Journal of Medicine · 29 Aug 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42670965
Open in JClub
Freely available genomic datasets for atrial fibrillation research: current resources and analytical pipeline.
Frontiers in Genetics · 24 Aug 2026 · Systematic Review
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42703458
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Weight Loss in Older Patients With Persistent Atrial Fibrillation: The LOSE-AF Randomized Clinical Trial.

Latest in Atrial Fibrillation Management and Outcomes

CARDIAC-FM: A Generalizable Multimodal Foundation Model Integrating ECG and Cardiac MRI

Image-based deep learning for emergency electrocardiogram classification

Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.

Freely available genomic datasets for atrial fibrillation research: current resources and analytical pipeline.

Browse JClub